Keywords: Orexigen, Takeda, Contrave, Licensing, Obesity drug, North America
Orexigen Therapeutics in $1 billion-plus deal with Japan’s Takeda for obesity drug Contrave in North America
Article | 03 September 2010
San Diego, USA-based Orexigen Therapeutics (Nasdaq: OREX) has entered into an agreement with Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
